Methods of reducing side effects of Anti-cd30 antibody drug conjugate therapy

Abstract

The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to U.S. Provisional Patent Application 62 / 580,261, filed November 1, 2017, and U.S. Provisional Patent Application 62 / 739,635, filed October 1, 2018, each of which is incorporated herein by reference. technical field [0003] The present invention generally relates to reducing side effects, such as e.g., cytotropic Approaches to neutropenia and peripheral neuropathy. Background technique [0004] T-cell lymphomas are a subset of aggressive non-Hodgkin's lymphomas (NHL), which account for approximately 10-15% of all newly diagnosed NHL cases in the United States. According to the 2008 World Health Organization (WHO) classification scheme, there are 18 subtypes of mature T-cell and natural killer (NK) cell neoplasms (Swerdlow 2008). Various subtypes of T- and NK-cell lymphomas are known to express the cell surface marker CD30; most notably, sALCL, where CD30 expression is a diagnostic m...

AI Technical Summary

Problems solved by technology

[0008] The high rate of subsequent disease progression in patients who respond to first-line therapy has led some investigators to adopt autologous stem cell transplantation (SCT) as a means to improve long-term outcomes; however, no randomized studies have been performed

Images